Raphael Clynes

15.7k total citations · 3 hit papers
99 papers, 11.2k citations indexed

About

Raphael Clynes is a scholar working on Immunology, Radiology, Nuclear Medicine and Imaging and Oncology. According to data from OpenAlex, Raphael Clynes has authored 99 papers receiving a total of 11.2k indexed citations (citations by other indexed papers that have themselves been cited), including 64 papers in Immunology, 42 papers in Radiology, Nuclear Medicine and Imaging and 26 papers in Oncology. Recurrent topics in Raphael Clynes's work include Monoclonal and Polyclonal Antibodies Research (41 papers), T-cell and B-cell Immunology (32 papers) and Immunotherapy and Immune Responses (24 papers). Raphael Clynes is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (41 papers), T-cell and B-cell Immunology (32 papers) and Immunotherapy and Immune Responses (24 papers). Raphael Clynes collaborates with scholars based in United States, France and Italy. Raphael Clynes's co-authors include Jeffrey V. Ravetch, Leonard G. Presta, Terri L. Towers, Amy Bergtold, Toshiyuki Takai, Diana L. Sylvestre, Min Li, Calin Dan Dumitru, Angela M. Christiano and Khadija Rafiq and has published in prestigious journals such as Science, Cell and Proceedings of the National Academy of Sciences.

In The Last Decade

Raphael Clynes

97 papers receiving 10.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets

2000 2.2k citations Raphael Clynes, Terri L. Towers et al. Nature Medicine profile →
FcR γ chain deletion results in pleiotrophic effector cell defects

1994 824 citations Toshiyuki Takai, Raphael Clynes et al. profile →
Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition

2014 652 citations Ali Jabbari, Jane Cerise et al. Nature Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Raphael Clynes United States	47	6.2k	3.7k	2.9k	2.7k	1.2k	99	11.2k
Guy Serre France	57	2.0k 0.3×	2.5k 0.7×	1.8k 0.6×	859 0.3×	270 0.2×	200	9.4k
Martino Introna Italy	62	6.6k 1.1×	1.7k 0.4×	4.0k 1.4×	3.0k 1.1×	135 0.1×	220	13.2k
Linda Muul United States	29	5.2k 0.8×	603 0.2×	3.0k 1.0×	4.1k 1.5×	199 0.2×	51	10.4k
Ulrich Schwab United Kingdom	13	1.4k 0.2×	901 0.2×	2.2k 0.8×	2.1k 0.8×	86 0.1×	32	7.3k
Mary K. Crow United States	66	8.5k 1.4×	1.6k 0.4×	2.4k 0.8×	2.1k 0.8×	56 0.0×	184	14.4k
Ashley R. Dunn Australia	50	4.9k 0.8×	624 0.2×	3.6k 1.3×	2.0k 0.7×	92 0.1×	101	10.0k
B J Nickoloff United States	45	3.5k 0.6×	330 0.1×	1.6k 0.6×	1.3k 0.5×	253 0.2×	79	6.9k
A K Bhan United States	32	3.4k 0.5×	1.3k 0.3×	1.1k 0.4×	802 0.3×	56 0.0×	52	6.4k
Gary S. Wood United States	53	3.3k 0.5×	445 0.1×	1.5k 0.5×	2.3k 0.8×	115 0.1×	174	9.7k
Pier Luigi Tazzari Italy	49	2.2k 0.4×	435 0.1×	3.6k 1.3×	1.4k 0.5×	196 0.2×	256	8.0k

Countries citing papers authored by Raphael Clynes

Since Specialization

Citations

This map shows the geographic impact of Raphael Clynes's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Raphael Clynes with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Raphael Clynes more than expected).

Fields of papers citing papers by Raphael Clynes

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Raphael Clynes. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Raphael Clynes. The network helps show where Raphael Clynes may publish in the future.

Co-authorship network of co-authors of Raphael Clynes

This figure shows the co-authorship network connecting the top 25 collaborators of Raphael Clynes. A scholar is included among the top collaborators of Raphael Clynes based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Raphael Clynes. Raphael Clynes is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

1.

Bupathi, Manojkumar, Siwen Hu‐Lieskovan, Sarina A. Piha‐Paul, et al.. (2023). 764 A phase 1, first-in-human (FIH), open-label, dose-finding and expansion study of XmAb808, a B7H3 x CD28 bispecific antibody, in combination with pembrolizumab in patients with advanced solid tumors. SHILAP Revista de lepidopterología. A859–A859. 3 indexed citations

2.

Norton, Nadine, Kathleen Tenner, Karla V. Ballman, et al.. (2018). Generation of HER2-specific antibody immunity during trastuzumab adjuvant therapy associates with reduced relapse in resected HER2 breast cancer. Breast Cancer Research. 20(1). 52–52. 11 indexed citations

3.

Knutson, Keith L., Raphael Clynes, Barath Shreeder, et al.. (2016). Improved Survival of HER2+ Breast Cancer Patients Treated with Trastuzumab and Chemotherapy Is Associated with Host Antibody Immunity against the HER2 Intracellular Domain. Cancer Research. 76(13). 3702–3710. 47 indexed citations

4.

Chen, James C., Jane Cerise, Ali Jabbari, Raphael Clynes, & Angela M. Christiano. (2015). Master Regulators of Infiltrate Recruitment in Autoimmune Disease Identified through Network-Based Molecular Deconvolution. Cell Systems. 1(5). 326–337. 20 indexed citations

5.

Norton, Nadine, Mark D. Pegram, Kathleen Tenner, et al.. (2014). Association Studies of Fcγ Receptor Polymorphisms with Outcome in HER2+ Breast Cancer Patients Treated with Trastuzumab in NCCTG (Alliance) Trial N9831. Cancer Immunology Research. 2(10). 962–969. 34 indexed citations

6.

Flores, Marcella, Dharmesh D. Desai, Bitao Liang, et al.. (2009). Dominant Expression of the Inhibitory FcγRIIB Prevents Antigen Presentation by Murine Plasmacytoid Dendritic Cells. The Journal of Immunology. 183(11). 7129–7139. 22 indexed citations

7.

Chen, Yali, Eitan M. Akirav, Wei Chen, et al.. (2008). RAGE Ligation Affects T Cell Activation and Controls T Cell Differentiation. The Journal of Immunology. 181(6). 4272–4278. 121 indexed citations

8.

Liang, Bitao, Craig D. Workman, Claude Chew, et al.. (2008). Regulatory T Cells Inhibit Dendritic Cells by Lymphocyte Activation Gene-3 Engagement of MHC Class II. The Journal of Immunology. 180(9). 5916–5926. 397 indexed citations

9.

Taylor, Clare, Dawn L. Hershman, Nina Shah, et al.. (2007). Augmented HER-2–Specific Immunity during Treatment with Trastuzumab and Chemotherapy. Clinical Cancer Research. 13(17). 5133–5143. 167 indexed citations

10.

Moser, Bernhard, Dharmesh D. Desai, Yali Chen, et al.. (2007). Receptor for Advanced Glycation End Products Expression on T Cells Contributes to Antigen-Specific Cellular Expansion In Vivo. The Journal of Immunology. 179(12). 8051–8058. 81 indexed citations

11.

He, Li-Zhen, Andrea Crocker, Laura Vitale, et al.. (2006). Targeting antigens to the human mannose receptor expressed in transgenic mice elicits potent CD4 and CD8 responses in vivo. Cancer Research. 66. 334–335. 1 indexed citations

12.

Bergtold, Amy, et al.. (2006). FcR-Bearing Myeloid Cells Are Responsible for Triggering Murine Lupus Nephritis. The Journal of Immunology. 177(10). 7287–7295. 88 indexed citations

13.

Curcio, Claudia, Emma Di Carlo, Raphael Clynes, et al.. (2003). Nonredundant roles of antibody, cytokines, and perforin in the eradication of established Her-2/neu carcinomas. Journal of Clinical Investigation. 111(8). 1161–1170. 97 indexed citations

14.

Curcio, Claudia, Emma Di Carlo, Raphael Clynes, et al.. (2003). Nonredundant roles of antibody, cytokines, and perforin in the eradication of established Her-2/neu carcinomas. Journal of Clinical Investigation. 111(8). 1161–1170. 23 indexed citations

15.

Rafiq, Khadija, Amy Bergtold, & Raphael Clynes. (2002). Immune complex–mediated antigen presentation induces tumor immunity. Journal of Clinical Investigation. 110(1). 71–79. 21 indexed citations

16.

Rafiq, Khadija, Amy Bergtold, & Raphael Clynes. (2002). Immune complex–mediated antigen presentation induces tumor immunity. Journal of Clinical Investigation. 110(1). 71–79. 195 indexed citations

17.

Clynes, Raphael, Terri L. Towers, Leonard G. Presta, & Jeffrey V. Ravetch. (2000). Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nature Medicine. 6(4). 443–446. 2154 indexed citations breakdown →

18.

Clynes, Raphael, et al.. (1999). Modulation of Immune Complex–induced Inflammation In Vivo by the Coordinate Expression of Activation and Inhibitory Fc Receptors. The Journal of Experimental Medicine. 189(1). 179–186. 317 indexed citations

19.

Fossati‐Jimack, Liliane, Luc Reininger, Yves Chicheportiche, et al.. (1999). High Pathogenic Potential of Low-Affinity Autoantibodies in Experimental Autoimmune Hemolytic Anemia. The Journal of Experimental Medicine. 190(11). 1689–1696. 66 indexed citations

20.

Weber, L W, Wilbur B. Bowne, Jedd D. Wolchok, et al.. (1998). Tumor immunity and autoimmunity induced by immunization with homologous DNA.. Journal of Clinical Investigation. 102(6). 1258–1264. 185 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact